In recent trading session, AbCellera Biologics Inc (NASDAQ:ABCL) saw 0.5 million shares changing hands at last check today with its beta currently measuring 0.43. Company’s recent per share price level of $3.33 trading at -$0.09 or -2.78% at last check today assigns it a market valuation of $977.72M. That most recent trading price of ABCL’s stock is at a discount of -141.74% from its 52-week high price of $8.05 and is indicating a discount of -0.6% from its 52-week low price of $3.35. Taking a look at company’s average trading volume volume of 1.30 million if we extend that period to 3-months.
AbCellera Biologics Inc (NASDAQ:ABCL) trade information
Upright in the red during last session for losing -2.78%, in the last five days ABCL remained trading in the red while hitting it’s week-highest on Friday, 06/07/24 when the stock touched $3.33 price level, adding 11.44% to its value on the day. AbCellera Biologics Inc’s shares saw a change of -41.77% in year-to-date performance and have moved -12.04% in past 5-day. AbCellera Biologics Inc (NASDAQ:ABCL) showed a performance of -12.96% in past 30-days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AbCellera Biologics Inc (ABCL) estimates and forecasts
Statistics highlight that AbCellera Biologics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -30.44% of value to its shares in past 6 months, showing an annual growth rate of -17.65% while that of industry is 15.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
In 2024, company’s earnings growth rate is likely to be around 6.32% while estimates for its earnings growth in next 5 years are of 10.00%.
ABCL Dividends
AbCellera Biologics Inc is more likely to be releasing its next quarterly report in July and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
